UNSPSC 51343106: Epervudine

This classification denotes a pyrimidine antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3G05PH9FAS. European Medicines Agency schedules Epervudine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06561MIG. Epervudine generally arises in the molecular formula C12H18N2O5.

UNSPSC 51343106 Epervudine is a Commodity code that nominally designates a specific antiviral pharmaceutical; however, recent state and local solicitation activity shows little alignment with this code's intended scope. The most recent opportunities tagged to this code involve naloxone (an opioid antagonist used in overdose response) and safe drug deactivation systems, neither of which are epervudine or related antivirals. State and local procurement offices appear to be using this code inconsistently or as a catch-all for pharmaceutical supply contracts that do not fit a more specific taxonomy. The issuing bodies on record include a state health department (Illinois Department of Public Health) and a county government (Seminole County, Florida), but the work being solicited—emergency response pharmaceuticals and harm-reduction supplies—diverges substantially from the code's pharmaceutical classification.

Geographically, the recent record shows activity in Illinois and Florida. The Illinois Department of Public Health awarded a completed piggyback pharmaceutical warehouse contract through the MMCAP Infuse cooperative purchasing vehicle to Chartwell Rx LLC on August 28, 2026, valued at $2.999 million over three years, though this award supplied doxycycline and ciprofloxacin, not epervudine. Seminole County, Florida issued an IFB (Invitation for Bid) on June 30, 2026 with a response deadline of July 26, 2026 (note: the source lists a 2023 date in the deadline field, likely a data error), seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a two-year initial term plus one-year renewal option. The code's recent activity is sparse and does not reflect genuine epervudine procurement; business development professionals should verify whether this code is the correct classification for pharmaceutical opportunities of interest before pursuing.